

REMARKS

Reconsideration of the Final Office Action mailed June 17, 2005, (hereinafter "instant Office Action") and withdrawal of the rejection of claims 1 and 3-13 are respectfully requested.

In the instant Office Action, claims 1 and 3-13 are listed as pending and claims 1 and 3-13 are listed as rejected.

The Examiner has not repeated the rejection of claims 1 and 3-4 under 35 U.S.C. §102(a) as allegedly being unpatentable over 6,323,243 or the rejection of claims 1 and 3-13 under 35 U.S.C. §103(a) as allegedly being unpatentable over 6,323,243. Applicants presume these rejections have been withdrawn and respectfully ask the Examiner to inform Applicants if this is not correct.

The Examiner has rejected claims 1 and 3-13 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 6,376,553. Applicants submit herewith a Terminal Disclaimer Applicants herewith submit a terminal disclaimer in compliance with 37 CFR 1.321(c). Therefore, the rejection of claims 1 and 3-13 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 6,376,553 is obviated and should be withdrawn.

If the Examiner believes that a telephone conference would advance the condition of the instant application for allowance, Applicants invite the Examiner to call Applicants' agent at the number noted below.

Date: March 23, 2006

Gayle O'Brien

Gayle O'Brien
Agent for Applicants
Reg. No. 48,812

Abbott Bioresearch Center, Inc.
100 Research Drive
Worcester, MA 01605
(508) 688-8053